Rezvilutamide by Jiangsu Hengrui Medicine for Liver Failure (Hepatic Insufficiency): Likelihood of Approval
Pharmaceutical Technology
JUNE 5, 2023
Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Liver Failure (Hepatic Insufficiency). Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Let's personalize your content